Steven Cohen Kiniksa Pharmaceuticals, Ltd. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.6 - $11.41 $2.51 Million - $3.76 Million	-329,798 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $637,552 - $848,012	-68,554 Reduced 17.21%	329,798 $3.28 Million
Q4 2021 Feb 14, 2022	BUY	$10.39 - $15.15 $241,588 - $352,267	23,252 Added 6.2%	398,352 $4.69 Million
Q3 2021 Nov 15, 2021	BUY	$11.39 - $16.23 $4.27 Million - $6.09 Million	375,100 New	375,100 $4.27 Million
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $2.91 Million - $4.2 Million	-219,800 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.68 - $23.97 $3.67 Million - $5.27 Million	219,800 New	219,800 $4.07 Million
Q4 2019 Feb 14, 2020	SELL	$5.24 - $12.96 $733,600 - $1.81 Million	-140,000 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$8.15 - $15.88 $855,750 - $1.67 Million	105,000 Added 300.0%	140,000 $1.19 Million
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.39 $462,000 - $713,650	35,000 New	35,000 $474,000
Q3 2018 Nov 14, 2018	SELL	$13.23 - $30.93 $66,150 - $154,650	-5,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$16.73 - $20.35 $83,650 - $101,750	5,000 New	5,000 $87,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $760M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.